WT1 126-134 peptide

WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL) . WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (Kd = 0.2 nM) with the humanized monoclonal antibody (IgG1) . WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies[1][2][3].

Product Specifications

CAS Number

[256952-63-3]

UNSPSC

12352209

Target

MHC

Related Pathways

Immunology/Inflammation

Field of Research

Cancer; Inflammation/Immunology

Smiles

O=C(N[C@@H](CCSC)C(N[C@@H](CC1=CC=CC=C1)C(N2[C@@H](CCC2)C(N[C@@H](CC(N)=O)C(N[C@@H](C)C(N3[C@@H](CCC3)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N

Molecular Formula

C52H77N13O12S

Molecular Weight

1108.31

References & Citations

[1]Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018 Jan 2;14 (1) :159-162.|[2]David A, et al, A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. Blood 2011; 118 (21) : 1677.|[3]Nakajima H, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021 Nov;70 (11) :3323-3335.